13 — HUTCHMED (China) Share News
0.000.00%
Last trade - 00:00
- HK$30.19bn
- HK$24.04bn
- $838.00m
- 79
- 15
- 57
- 49
RCS - Hutchmed China Ltd - NDA Acceptance in China for Fruquintinib
AnnouncementRCS - Hutchmed China Ltd - Presentations at AACR Annual Meeting 2023
AnnouncementREG - Hutchmed China Ltd - Intended Retirement of Independent NED
AnnouncementREG - Hutchmed China Ltd - 2022 Annual Report and Notice of AGM
AnnouncementRCS - Hutchmed China Ltd - HUTCHMED Initiates Registration Phase Enrollments
AnnouncementREG - Hutchmed China Ltd - Total Voting Rights
AnnouncementRCS - Hutchmed China Ltd - Rolling Submission of Fruquintinib US NDA Complete
AnnouncementRCS - Hutchmed China Ltd - Closing of Fruquintinib License to Takeda
AnnouncementREG - Hutchmed China Ltd - Director's Share Dealing
AnnouncementREG - Hutchmed China Ltd - Vesting of awards under the LTIP
AnnouncementRCS - Hutchmed China Ltd - Publication of Form 20-F
AnnouncementREG - Hutchmed China Ltd - 2022 Full Year Results and Business Updates
AnnouncementRCS - Hutchmed China Ltd - Enrollment Completed in Phase 2 Amdizalisib trial
AnnouncementREG - Hutchmed China Ltd - Notice of Results
AnnouncementREG - Hutchmed China Ltd - License to Takeda for Fruquintinib outside China
AnnouncementREG - Hutchmed China Ltd - Inclusion of ORPATHYS in NRDL in China
AnnouncementRCS - Hutchmed China Ltd - Enrollment Completed in Phase 3 Trial
AnnouncementREG - Hutchmed China Ltd - Blocklisting Six Monthly Return
AnnouncementRCS - Hutchmed China Ltd - FDA NDA Rolling Submission for Fruquintinib
Announcement